Status:
UNKNOWN
Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer
Lead Sponsor:
The Comprehensive and Integrative Medicine Institute of South Korea
Conditions:
Cancer
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Most cancer patients experience multiple symptoms related to chemotherapy and use CAM (complementary and alternative medicine) as an adjunct to conventional treatment. Moxibustion is traditional Korea...
Eligibility Criteria
Inclusion
- Diagnostic histopathology of cancer
- Performance status of 0-2 on the European Cooperative Oncology Group (ECOG) performance scale.
- Patients on chemotherapy currently have plan to receive chemotherapy for more than 6 weeks.
- Follow-up possible during the clinical trial
- Informed signed consent
Exclusion
- Patients with Severe Heart disease and hypertension that is not controlled (systolic blood pressure \>160 or Diastolic blood pressure \>100)
- Patients with diabetes that is not controlled (FBST \>180 or BST\>250)
- Patients with abdominal injury or severe ascites can't be received moxibustion therapy on abdomen.
- Hypersensitive section to moxibustion treatment
- Inability to comprehend or express oneself in the Korean language
- An Individual deemed to be ineligible by a physician
- Refusal to participate in this trial or to provide informed consent.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02261571
Start Date
October 1 2014
End Date
September 1 2015
Last Update
October 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deagu Hanny University Medical center
Deagu, South Korea, 704-123